Ignite Creation Date:
2024-05-05 @ 10:58 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01220076
Status:
COMPLETED
Last Update Posted:
2021-03-12
First Post:
2010-10-11
Brief Title:
Biological Response to Tamoxifen TAM in Patients With Breast Cancer Non Metastatic RH
Sponsor:
Institut Cancerologie de lOuest
Organization:
Institut Cancerologie de lOuest
Study Overview
Official Title:
Phase II Study Evaluating According to the Polymorphism of CYP2D6 the Rate of Biological Response to Treatment With Tamoxifen TAM Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TAM
Brief Summary:
The biological response to treatment with tamoxifen in the preoperative situation is studying in this protocol This study will enrolls patients with non-metastatic breast cancer HR
The relationship between the CYP2D6 polymorphism pharmacokinetics and biological efficacy of TAM will be studied
The relationship between the CYP2D6 polymorphism pharmacokinetics and biological efficacy of TAM will be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None